ProCE Banner Activity


Disparities in Outpatient COVID-19 Diagnosis, Treatment, and Outcomes


In this on-demand webcast, expert faculty discuss disparities in outpatient COVID-19 management and strategies to overcome them.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: May 10, 2023

Expiration: May 09, 2024

No longer available for credit.



Lakesha M. Butler

Lakesha M. Butler, PharmD, CDFT

Associate Vice President for Inclusion, Diversity, Health Equity
Chief Diversity Officer, UF Health
Clinical Professor,
Department of Pharmacotherapy and Translational Research
University of Florida
Gainesville, Florida

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Pfizer Inc.

Pfizer, Inc.

Target Audience

This program is intended for physicians, pharmacists, and other HCPs involved in the management of nonhospitalized patients with current or previous COVID-19, including both specialists and primary care providers. This identified target audience will benefit from this education by gaining the knowledge and strategies necessary to individualize outpatient management of acute COVID and post-COVID conditions.

Program Learning Goal

To improve healthcare professionals’ (HCPs) competence in optimizing outpatient management of COVID-19, including timely diagnosis, risk stratification, and treatment, and to expand HCPs’ ability to apply emerging data on the epidemiology, presentation, and emerging data regarding prevention and management of post-COVID conditions.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement strategies to ensure equitable and timely COVID-19 testing and diagnosis

  • Use best practices for risk stratification of non-hospitalized patients with COVID-19 to determine eligibility for outpatient treatment

  • Apply approaches to preventing and managing post-COVID conditions based on emerging data and current best practices


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Lakesha M. Butler, PharmD, CDFT

Associate Vice President for Inclusion, Diversity, Health Equity
Chief Diversity Officer, UF Health
Clinical Professor,
Department of Pharmacotherapy and Translational Research
University of Florida
Gainesville, Florida

Lakesha M. Butler, PharmD, CDFT, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 10, 2023, through May 09, 2024:

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. View and study the content in its entirety.
  3. Submit answers to the posttest questions and evaluation questions online.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for a discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Continuing Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number -  JA4008176-0000-23-132-H01-P

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.